Status:
UNKNOWN
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma
Lead Sponsor:
Seoul National University Hospital
Conditions:
Papillary Thyroid Microcarcinoma
Thyroid Cancer
Eligibility:
All Genders
19-60 years
Phase:
NA
Brief Summary
This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.
Detailed Description
For treatment of papillary thyroid microcarcinoma (PTMC), radiofrequency ablation (RFA) will be performed with the supine position and neck extended under ultrasonogrphic guidance. Before RFA, local a...
Eligibility Criteria
Inclusion
- who agrees to the consent form
- aged from 19 to 60 years old
- who has been diagnosed with Bethesda category V or VI by fine needle aspiration or needle biopsy
- whose thyroid cancer is 1 cm or smaller than 1 cm length
- who does not have lymph node or distant metastasis
- whose thyroid cancer does not have extrathyroidal extension
- in whom it seems technically possible to completely ablate thyroid cancer using RF
Exclusion
- who cannot routinely followed up according to the study schedule
- who has been with Bethesda category I, II, III, or IV by fine needle aspiration or needle biopsy.
- who has hyperthyroidism that requires treatment
- who has bleeding tendency
- multifocal papillary thyroid microcarcinoma
- who is pregnant
Key Trial Info
Start Date :
April 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03432299
Start Date
April 16 2018
End Date
December 31 2023
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080